{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007004","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.285350+00:00","generated_at":"2026-05-17T00:20:40.982542+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Therapeutics Q3 2025 net loss $14.3M; cash $220M; tovecimig OS/PFS data late Q1 2026","bullets":["Net loss Q3 2025 $14.3M ($0.08/share) vs $10.5M ($0.08) Q3 2024; nine-month loss $50.8M ($0.34).","Cash and marketable securities $220M as of Sep 30, 2025, up from $127M Dec 2024; cash runway through 2028.","Tovecimig: OS and PFS data from Phase 2/3 COMPANION-002 in BTC expected late Q1 2026.","CTX-8371 Phase 1 fully enrolled, no DLTs; cohort expansions in NSCLC and TNBC start Q4 2025; data H1 2026.","CTX-10726 IND filing on track for Q4 2025; initial Phase 1 data expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007004","json":"https://secwatch.observer/filing/0001171843-25-007004.json","markdown":"https://secwatch.observer/filing/0001171843-25-007004.md","text":"https://secwatch.observer/filing/0001171843-25-007004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325007004/0001171843-25-007004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325007004/f8k_103125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:20:40.982542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}